Childhood adversity is associated with worse biological health and an elevated risk for many major health problems.
For patients with type 2 diabetes (T2D) and opioid use disorder (OUD), semaglutide is associated with a significantly lower risk for opioid overdose compared with other antidiabetic medications.
For patients with obesity, the addition of semaglutide to standard hidradenitis suppurativa (HS) treatments yields improvement in quality of life and a reduction in flares.